Chemoproteomics studies have uncovered multiple potential kinase drug targets in the Plasmodium protozoan that causes malaria, and subsequent screening of approved kinase inhibitor drugs has now thrown up several hits with lethal activity at different stages of the complex life cycle of the parasite. Researchers at the University of Cape Town, South Africa, working with scientists at Glaxosmithkline plc, describe the activity in Plasmodium of one of these kinase inhibitors, the cancer drug sapanisertib, in a paper appearing in Science Translational Medicine, Oct. 19, 2022.

The 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway, a metabolic pathway for the...

Researchers have identified a compound, ML-901, that showed highly specific and potent inhibition of the malaria parasite.

An international collaborative study has identified several novel derivatives of anticancer proteasome inhibitors (PIs) that had potential as antimalarials, the authors reported in the September 28, 2021, online edition of Proceedings of the National Academy of Sciences.

Hemex Health Inc.’s newborn screening for sickle cell disease substantially reduces the labor involved for parents and providers in testing for the potentially fatal condition. The test had previously been able to test infants 6 weeks and older on the company’s Gazelle platform.

A collaboration aimed at identifying and developing potential new antimalarial drug candidate drugs has been announced between Walter and Eliza Hall Institute for Medical Research in Melbourne, Australia, and Janssen Pharmaceutica, with assistance from Johnson & Johnson Innovation.